Abstract 2930
Background
Early diagnosis of cancer is an important factor in increasing success in treatment. Nursing and nursing students who take care of the patient in clinical area practices can have a major impact on the disease by providing early diagnosis of the cancer. Limited study was explored awareness of nursing student about the warning signs of cancer.
Methods
A cross-sectional descriptive study was conducted from January-March 2019. The sample size was measured Raosoft online calculator programme. A total of 460 nursing students participated in this study. Data was was obtained from nursing student via self-report using the data collection form developed by researchers based on literature. The Chi-square test was performed to evaluate differences among groups.
Results
The mean age of the nursing students was 20.05 ± 2.04; most of the students were female (82.6%). The knowledge level of warning signs of cancer of the students who were female was significantly higher than male students; as following; the symptoms of change in bowel or bladder habits (p = 0.001); unusual bleeding or discharge (p = 0.01); thickening or lump in the breast or elsewhere (p = 0.004); indigestion or difficulty in swallowing (p = 0.002); obvious change in a wart or mole (p = 0.003); nagging cough or hoarseness (p = 0.04). The knowledge level of warning signs of cancer of the students who took ’Internal Medicine Nursing’ lesson was significantly higher than others; as following; the symptoms of change in bowel or bladder habits (p = 0.000); a sore that doesn’t heal (p = 0.002); unusual bleeding or discharge (p = 0.03); indigestion or difficulty in swallowing (p = 0.000); obvious change in a wart or mole (p = 0.000); nagging cough or hoarseness (p = 0.001).
Conclusions
It is thought that the majority of nursing students know warning signs of the cancer and are associated with the education given in ’Internal Medicine Nursing’. It is recommended that nursing students take part in early diagnosis and screening programs in cancer. Female nursing students more aware than male students. Because; cancer prevention campaigns have focused breast and cervical cancer which involves only females. Cancer prevention campaigns should be organized for lung, prostate and colorectal cancer which are more common in men.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3630 - Results of phase 1 clinical trial of high doses of Seleno-L-methionine (SLM) in sequential combination with Axitinib in previously treated and relapsed clear cell renal carcinoma (ccRCC) patients
Presenter: Yousef Zakharia
Session: Poster Display session 3
Resources:
Abstract
2356 - Safety and Efficacy of CDX-014 , an Antibody-Drug Conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced Renal Cell Carcinoma
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
1028 - SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz).
Presenter: Begona P. Valderrama
Session: Poster Display session 3
Resources:
Abstract
2293 - Effect of Antacid Intake on the Therapeutic Efficacy of Sunitinib (SUN) in Metastatic Renal Cell Carcinoma (mRCC) Patients (pts): a Sub-Analysis of the STAR-TOR Registry
Presenter: Katrin Schlack
Session: Poster Display session 3
Resources:
Abstract
1451 - Randomized phase 3 trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN Renal 101 Japanese subgroup analysis
Presenter: Motohide Uemura
Session: Poster Display session 3
Resources:
Abstract
4399 - Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)
Presenter: Jindrich Finek
Session: Poster Display session 3
Resources:
Abstract
1344 - Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials
Presenter: Kyaw Thein
Session: Poster Display session 3
Resources:
Abstract
3462 - A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
5268 - Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)
Presenter: Sophie Hans
Session: Poster Display session 3
Resources:
Abstract
4235 - First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES Study
Presenter: Cristina Masini
Session: Poster Display session 3
Resources:
Abstract